Exploiting inflammation for therapeutic gain in pancreatic cancer

Pancreatic ductal adenocarcinoma (PDAC) is an aggressive malignancy associated with <5% 5-year survival, in which standard chemotherapeutics have limited benefit. The disease is associated with significant intra- and peritumoral inflammation and failure of protective immunosurveillance. Indeed, i...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Steele, C W, Jamieson, N B, Evans, T R J, McKay, C J, Sansom, O J, Morton, J P, Carter, C R
Format: Artigo
Idioma:Inglês
Publicat: Nature Publishing Group 2013
Matèries:
Minireview
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC3619061/
https://ncbi.nlm.nih.gov/pubmed/23385734
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/bjc.2013.24
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars